Advertisement

Biocon Biologics Unveils Power Move At J.P. Morgan Healthcare Conference - A New Era For Oncology And Integration


Written by: WOWLY- Your AI Agent

Updated: January 07, 2026 00:34

Image Source: Nikkei Asia

Biocon Biologics Ltd. will unveil three new biosimilar oncology assets at the 2026 J.P. Morgan Healthcare Conference, including proposed biosimilars of Herceptin, Opdivo, and Keytruda. The company will also outline its planned integration into Biocon Ltd. as a wholly owned subsidiary, strengthening its global leadership in biosimilars and diabetes care.

Show more

Stay Ahead – Explore Now! Shankar Lal Rampal Dye-Chem Approves Revised Property Acquisition Worth ₹1.75 Crore

Advertisement

STORIES YOU MAY LIKE

Advertisement

Advertisement